Skip to main content

Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo

Buy Article:

$48.00 plus tax (Refund Policy)

Abstract:

Abstract

Aim: To investigate the antitumor activities of an anti-ErbB2 scFv-Fc-interleukin 2 (IL-2) fusion protein (HFI) in vitro and in vivo.Methods: Fusion pr otein HFI was constructed. The efficacy of HFI in mediating tumor cell lysis was determined by colorimetric lactate dehydrogenase release assays. The antitumor activity of HFI was evaluated in tumor xenograft models. Results: The fusion protein was folded as a homodimer formed by covalently linking Fc portions and it retained ErbB2 specificity and IL-2 biological activity. HFI mediated antibody-dependent cell-mediated cytotoxicity (ADCC) at low effector-to-target ratios in vitro and improved the therapeutic efficacy of IL-2 in experiments in vivo.Conclusion: The genetically-engineered anti-ErbB2 scFv-Fc-IL-2 fusion protein exhibited high efficiency both in mediating ADCC in vitro and significant antitumor activity in tumor xenograft models.

Keywords: ErbB2; antibody; fusion protein; interleukin-2; tumor

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1745-7254.2007.00622.x

Affiliations: 1: Institute of Basic Medical Sciences, Beijing 100850, China 2: Institute of Basic Medical Sciences, The Academy of Medical Science of Shandong Province, Ji-nan 250062, China 3: 301 Hospital, Beijing 100853, China

Publication date: October 1, 2007

bsc/aphs/2007/00000028/00000010/art00014
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more